HiFiBio partners with CoVIC for SARS-CoV-2 antibody therapies

By The Science Advisory Board staff writers

August 17, 2020 -- HiFiBio Therapeutics and the Coronavirus Immunotherapy Consortium (CoVIC) will collaborate to develop SARS-CoV-2-neutralizing antibodies with potential therapeutic and prophylactic applications.

HiFiBio has submitted 10 distinct mono- and bispecific antibodies to CoVIC for in vitro and in vivo testing. The company will get a first look into the performance of its antibodies compared to other submitted antibodies and will explore synergies among them for potential combinational therapies. Together, the collaboration seeks to accelerate development pipelines to protect vulnerable individuals from COVID-19 and bring successful immunotherapies to COVID-19 patients.

The antibodies were developed by leveraging HiFiBio's proteomics and proprietary single-cell profiling technologies. The company's Drug Intelligent Science technology allows antibody therapies to be matched with biomarkers to predict patient response.

The company is also preparing an investigational new drug application with the U.S. Food and Drug Administration for HFB30132A, a SARS-CoV-2-neutralizing antibody for the treatment of COVID-19 patients. The antibody has been evaluated in preclinical studies and a phase I clinical study is planned for later this summer.

Bio-Techne releases new SARS recombinant antibody
Bio-Techne has launched a SARS-CoV-1/2 spike receptor-binding domain LlamaBody recombinant antibody that blocks the virus from binding to the host receptor,...
Twist Bioscience, Seismic Bio partner to discover bispecific antibodies
Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.
Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit...
ExeVir wins backing to develop llama-derived antibodies for COVID-19
Belgian firm ExeVir Bio has closed on a 23-million euro ($26.9 million U.S.) series A financing round to support the development of its llama-derived...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter